Zymeworks/ZYME

$9.25

-1.17%
-
1D1W1MYTD1YMAX

About Zymeworks

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.

Ticker

ZYME

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Kenneth Galbraith

Employees

272

Headquarters

Middletown, United States

Zymeworks Metrics

BasicAdvanced
$652.76M
Market cap
-
P/E ratio
-$1.74
EPS
1.13
Beta
-
Dividend rate
$652.76M
1.12826
$13.14
$6.02
546.61K
7.405
0.02
0.026
-19.3%
-24.78%
-22.01%
8.588
1.408
1.527
-81.57%
-198.69%
24.96%

What the Analysts think about Zymeworks

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 9 analysts.
58.16% upside
High $21.00
Low $10.00
$9.25
Current price
$14.63
Average price target

Zymeworks Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-85.2% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$16.9M
2.42%
Net income
$-14.4M
-49.65%
Profit margin
-85.2%
-50.85%

Zymeworks Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 53.89%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.36
-$0.76
-$0.41
-$0.20
-
Expected
-$0.54
-$0.47
-$0.47
-$0.43
-$0.29
Surprise
-32.91%
61.55%
-12.65%
-53.89%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Zymeworks stock?

Zymeworks (ZYME) has a market cap of $652.76M as of April 14, 2024.

What is the P/E ratio for Zymeworks stock?

The price to earnings (P/E) ratio for Zymeworks (ZYME) stock is 0 as of April 14, 2024.

Does Zymeworks stock pay dividends?

No, Zymeworks (ZYME) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Zymeworks dividend payment date?

Zymeworks (ZYME) stock does not pay dividends to its shareholders.

What is the beta indicator for Zymeworks?

Zymeworks (ZYME) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Zymeworks stock price target?

The target price for Zymeworks (ZYME) stock is $14.63, which is 58.16% above the current price of $9.25. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Zymeworks stock

Buy or sell Zymeworks stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing